Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma

: Aggressive T cell lymphomas are a subgroup of lymphomas with a particularly poor prognosis. This is especially true for patients with recurrent or refractory disease, who typically have limited response to salvage therapy and extremely poor overall survival. For this reason, there is a strong need to develop potentially active drugs for these malignancies. Pralatrexate is a novel antifolate designed to have high affinity for reduced folate carrier type 1. Preclinical and clinical studies have demonstrated that pralatrexate has significant activity against T cell lymphomas. The dose-limiting toxicity for pralatrexate is mucositis, which can be abrogated with folic acid and vitamin B12 supplementation. Pralatrexate is the first single agent approved for the treatment of patients with relapsed or refractory peripheral T cell lymphoma. This approval was based on an overall objective response rate observed in the pivotal study. The overall response rate was 29%, with a median duration of 10.1 months. This article reviews the biochemistry, preclinical experience, metabolism, and pharmacokinetics of pralatrexate, including the clinical experience with this agent in lymphoma. Future areas of development are now focused on identifying synergistic combinations of pralatrexate with other agents and the evaluation of predictive markers for clinical benefit.

[1]  J. Vose,et al.  Peripheral T-cell lymphoma. , 2011, Blood.

[2]  K. Savage,et al.  Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  I. Bièche,et al.  Single agent and combination studies of pralatrexate and molecular correlates of sensitivity , 2010, British Journal of Cancer.

[4]  R. Pazdur,et al.  Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary , 2010, Clinical Cancer Research.

[5]  R. Advani,et al.  Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results. , 2009 .

[6]  S. Horwitz,et al.  Stem Cell Transplant (SCT) and Pralatrexate Therapy: Outcome of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Who Received SCT Prior to or Following Pralatrexate Therapy. , 2009 .

[7]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Molina,et al.  Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. , 2008, IDrugs : the investigational drugs journal.

[9]  P. Mclaughlin,et al.  CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. , 2008, Journal of the American Academy of Dermatology.

[10]  A. Fotoohi,et al.  Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells , 2008, Leukemia & lymphoma.

[11]  D. Mould,et al.  A Population Pharmacokinetic and Pharmacodynamic Evaluation of Pralatrexate in Patients with Hematologic Malignancies. , 2007 .

[12]  A. Zelenetz,et al.  Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma , 2007, British journal of haematology.

[13]  Y. Assaraf.  Molecular basis of antifolate resistance , 2007, Cancer and Metastasis Reviews.

[14]  O. O’Connor,et al.  Pralatrexate: an emerging new agent with activity in T-cell lymphomas , 2006, Current opinion in oncology.

[15]  A. Zelenetz,et al.  461 POSTER Early phase experience with pralatrexate (10-propargy l-10-deazaaminopterin [PRX]), a novel antifolate with high afnity forthe reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies , 2006 .

[16]  J. Teruya-Feldstein,et al.  The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma , 2006, Clinical Cancer Research.

[17]  C. Patte.  Treatment of mature B-ALL and high grade B-NHL in children. , 2002, Best practice & research. Clinical haematology.

[18]  B. Nathwani,et al.  Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  M. Kris,et al.  Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  P. Gaulard,et al.  Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  D. Weisenburger,et al.  Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[23]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[24]  W. Gregory,et al.  Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma. , 1993, British Journal of Cancer.

[25]  F. Sirotnak,et al.  Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. , 1993, Journal of medicinal chemistry.

[26]  E. Cadman,et al.  Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells. , 1979, The Journal of clinical investigation.

[27]  S. Kurup,et al.  Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II. , 2008, Anti-cancer agents in medicinal chemistry.

[28]  F. Sirotnak,et al.  New folate analogs of the 10-deaza-aminopterin series Basis for structural design and biochemical and pharmacologic properties , 2004, Cancer Chemotherapy and Pharmacology.

[29]  A. Evens,et al.  Treatment of T-cell non-hodgkin’ lymphoma , 2004, Current treatment options in oncology.

[30]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[31]  A. López-Guillermo,et al.  Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.